Arrowhead CEO: We feel 'great' about our hepatitis B drug

Arrowhead CEO: We feel great about the drug
Arrowhead CEO: We feel great about the drug   

Shares of Arrowhead Research took a tumble last month when data on its experimental hepatitis B drug ARC-520 disappointed investors, prompting the company's CEO to write a letter to investors defending the compound and the company's communications around it.

Chief Executive Chris Anzalone contends the data the company reported were strong, saying Monday in an interview at the American Association for the Study of Liver Diseases that increased doses may provide the efficacy investors are looking for.

Arrowhead is one of many gearing up to tackle hepatitis B, a disease many consider to be the next frontier after hepatitis Cnow being tackled by Gilead Sciences, Merck, AbbVie and others. Hepatitis B affects as many as 350 million people worldwide, according to the World Health Organization.

Read MoreStocks to watch ahead of liver disease conference